Jasper Therapeutics (NASDAQ:JSPR) Posts Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Jasper Therapeutics (NASDAQ:JSPR) released its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17, FiscalAI reports.

Jasper Therapeutics Trading Down 8.5%

Shares of JSPR traded down $0.07 during trading hours on Friday, reaching $0.79. 567,510 shares of the company traded hands, compared to its average volume of 2,265,872. The firm has a market cap of $22.12 million, a price-to-earnings ratio of -0.24 and a beta of 3.02. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $3.14. The stock’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.91.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its position in Jasper Therapeutics by 6,394.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after buying an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC bought a new position in Jasper Therapeutics in the 3rd quarter worth about $3,291,000. Velan Capital Investment Management LP increased its position in shares of Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the period. Woodline Partners LP purchased a new position in shares of Jasper Therapeutics during the third quarter worth approximately $2,475,000. Finally, Millennium Management LLC increased its position in shares of Jasper Therapeutics by 194.2% during the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Wall Street Zen lowered Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Piper Sandler assumed coverage on Jasper Therapeutics in a report on Wednesday. They issued an “overweight” rating and a $2.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.17.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.